Ann: Outstanding SubB2M Ovarian Cancer Test Data, page-480

100%/100% is incredible - and I wouldn’t be surprised to see this come to market very quickly.
I had a client who had a delayed prostrate cancer diagnosis and due to delay it metastasised and he died within approx 12 months. When looking deeply into the research on PSA - what it showed was a) it was really only a feeder into surgical biopsy to definite diagnosis but by monitoring the ‘rises’ over consecutive years it could give an earlier indicator, still not precise. what i see happening with B2M - is yearly screening tests for at risk populations & any year on year rises in the levels present for ‘early stage’ will be able to be determined by algorithmic analysis as to what specific % of rise determines referral for surgical biopsy.

huge implications for the treatment of cancer